The medical management of angina pectoris requires a comprehensive approach to the patient and his family, including attention not only to established physiologic and pharmocologic principles, but also to the emotional aspects of his illness. When comprehensive management is systematically and rigorously applied to the patient with angina pectoris, excellent relief of the symptoms of angina pectoris can be achieved in a high percentage of patients, although there are significant numbers of patients who are refractory to the most intensive management using presently available drugs. The same fundamental principles of care apply to patients with coronary heart disease who undergo aortocoronary bypass surgery and to those treated medically.
THE IMPORTANCE of diagnosing angina pectoris derives from the implicit threat of imminent sudden death. The fear and anxiety engendered by this diagnosis, rather than the severity of the ischemic pain, make this diagnosis of such extreme clinical importance. 1 The possibility of sudden death or infarction has spawned a major industry: coronary bypass surgery.
A frequently cited indication for coronary artery bypass surgery is "relief of intractable angina," but if surgical therapy were conclusively shown not to prolong life or prevent infarction, the annual number of coronary bypass procedures would probably decline precipitously. Few patients with angina pectoris continue to have frequent episodes of severe pain despite intensive medical treatment. Thus, a very high percentage of patients undergo bypass surgery to prevent premature death and myocardial infarction or to allow increased activity free of anginal pain. It is not clear what percentage of patients whose angina is considered refractory to medical management have had intensive medical care before being so classified. A major purpose of this review is to examine the aspects of medical management that constitute comprehensive care.
There are four fundamental aspects of management (table 1): early detection of the disease and accurate assessment of its extent; education of the patient, the family, and the community as to the facts of the disease and methods of care; modification of lifestyle to prevent ischemia and provide optimal control of coronary risk factors; and the administration of medication to control the clinical manifestations of chronic coronary heart disease. These general considerations apply to all patients regardless of whether they have surgery in addition to medical care.
Detection and Assessment of Angina Pectoris
The Importance of an Accurate Diagnosis The first step in comprehensive management of chronic coronary heart disease is an accurate From the Cardiovascular Laboratory, St. Elizabeth's Hospital, Beaumont, Texas. diagnosis, not only qualitatively but also quantitatively (table 2).2 Such a diagnosis includes an accurate assessment of the presence or absence of coronary artery disease, (including the possibility of coronary spasm), the extent of coronary stenosis, the functional condition of the left ventricle, the electrophysiologic state of the heart as it predisposes to potentially lethal arrhythmias, and the overall functional (aerobic) capacity of the body. These factors are strongly related to the long-term prognosis of the patient and, in current practice, largely determine the decision for medical or surgical therapy. However, an accurate diagnosis is of great importance even if surgery is not being considered. An erroneous diagnosis of coronary disease may have grave consequences because it can severely impair the quality of life, especially in younger people, by limiting unnecessarily their employability, insurability and physical activity (table  3) . In older people, a false-positive diagnosis may result in premature retirement, repetitive but unnecessary hospital admissions and long-term exposure to potentially hazardous medications. Alternatively, there can be fatal consequences if serious coronary disease is missed or if another major heart disease with concomitant angina is overlooked.
Methods of Diagnosis
The classic method of diagnosing angina pectoris, and still one of great clinical importance, is the acquisition of an accurate and comprehensive medical history (table 4). The predictive value for the medical history considered as a test for ischemic heart disease is shown in table 5. These data, derived by Diamond and Forrester from several published studies, show the results of comparisons of the clinicians' impressions with the presence or absence of significant coronary occlusive disease as determined by coronary arteriography.3 If the pain history was considered to be typical of angina pectoris in the highly selected patients of these studies, 90% of the patients were found to have hemodynamically significant coronary stenosis at coronary arteriography. If the pain had features suggesting myocardial ischemia but was atypical in one or more important ways, then significant coronary stenosis was found in 50%. If the clinician classified the pain as definitely not angina, the percentage of patients with coronary stenosis decreased to approximately 16%. From these figures, the medical history although the history is of unquestionable value, one must use more objective tests as well.
One of the important roles of the medical history, when taken with the age and sex of the patient, is to provide an "'initial probability" of coronary heart disease according to the Bayes theorem.3 'This is crucial to the reasonable application of other diagnostic tests, including the treadmill ECG and radionuclide studies.3A5 When properly applied and interpreted, the exercise ECG provides important information for diagnosis ' and prognosis.7'8 More recently, there has been a great interest in radionuclide studies of myocardial perfusion and ventricular function at rest and during exercise. These studies have great potential value in medical diag- 88.9 ± 0.7% *Standard error of the percent. These values establish statistical levels of error, but do not include errors due to sampling bias and other factors, which are probably of greater magnitude.
Adapted from Diamond and Forrester.3 nosis.Y' 10 These tests can greatly facilitate diagnosis and, when properly performed and interpreted, can provide firm data upon which to base diagnostic and nonsurgical therapeutic decisions in properly selected patients who otherwise would have required coronary arteriography. Radionuclide studies also provide new insights into the mechanical consequences of coronary stenosis 'and afford new methods for assessment of the effect of coronary surgery on ventricular function during exercise and at rest. Such studies demonstrate that the deterioration of ventricular function during exercise that characterizes significant coronary stenosis is generally prevented by effective surgical revascularization."1 Despite the exciting advances in nuclear cardiology, coronary arteriography and left ventricular angiography remain the standard for the definitive diagnosis of coronary heart disease.12 From this combined'study come data that often provide unequivocable evidence of the presence or absence of significant coronary artery atherosclerosis, the location and severity of the lesions that are present, and the extent of coronary collateral circulation. Spontaneous or induced coronary spasm can be visualized and its response to various'medication assessed."3 16 Important new concepts of coronary vasomotion have been derived relating to variant angina and to the precipitation of acute myocardial infarction and the development of unstable angina."'"' The left ventricular angiogram with single or biplane recording provides data for estimating left ventricular ejection fraction and segmental wall motion.
Prognostic Value of Coronary Arteriography and Left Ventricular Angiography
Coronary arteriography and left ventricular angiography also provide information about the prob-ability of survival and of future coronary events. Table  6 presents data from an early report of Bruschke and colleagues,18' showing the combined influence' of the extent of coronary stenosis and the extent of left ventricular wall motion abnormality or scarring' upon the survival of coronary heart disease patients who underwent both coronary arteriography'and left ventricular angiography. The power of the prognostic information is 'shown clearly in this table. A spectrum of subclasses is formed by this matrix, with mortality rates varying from almost zero in 5 years in those with onevessel'disease and normal left ventricular function to a greater than 50% 5-'year mortality in those with threevessel disease and diffusely impaired left ventricular function. These correlations have been confirmed repeatedly in substance, though more recent studies have suggested an overall improvement of survival. Data such as these provide the basis upon which clinicians recommend coronary bypass surgery.
Other Factors Relating to Prognosis
A third major factor relating to the prognosis of persons with coronary disease is the electrophysiologic state of the heart insofar as it predisposes to potentially lethal cardiac arrhythmias. This factor has been shown to be one of the three major determinants of survival in these patients. The studies of Cobb and associates"' of the survivors of out-ofhospital cardiac arrest illustrates this principle. A major fraction of these survivors did not have an acute myocardial infarction or power failure; rather, they sustained primary cardiac arrest as a result 'of arrhythmia. Many of the patients had significant stenosis of only one major coronary artery. Additional evidence supporting the impact of the electrophysiologic condition of the heart on survival has been' provided by Schulze and colleagues.20 The combination of ventricular dysfunction, as measured by radionuclide studies, and ventricular arrhythmias recorded by ECG monitors had very strong prognostic significance in patients who survived acute myocardial' infarction.
The Prognostic Value of the Treadmill Test
The prognostic value of the exercise ECG test has been recognized for many "years.21-23 Its value has recently been emphasized by McNeer et al.7 who examined the prognostic significance of graded treadmill exercise tests, using the Bruce protocol, in 1442 patients who also underwent coronary arteriography. They found a very strong correlation between prob- ability of survival and duration of exercise that was tolerated, not only for all patients treated medically, but even more impressively for those shown to have significant coronary stenosis by coronary arteriography. Thus, of the patients with significant coronary disease who finished stage 3 and started stage 4 of the Bruce protocol, 99% were alive at 12 months and 90% at 48 months. By using a combination of exercise variables, the entire cohort could be divided into highand low-risk subgroups. The low-risk group comprised 876 (74%) of the nonsurgical patients. Of these, 574 had significant coronary disease, but had either an exercise endurance of more than 9 minutes or had no ischemic ST depression at heart rates greater than 160 beats/min or 85% of the predicted maximum. Survival in these patients was 99% at 12 months and 93% at 48 months. In contrast, 34 patients (1 1%) in the medically managed group had positive ST depression on the ECG in stages 1 or 2. Fifteen percent of these patients were dead in 1 year and 37% were dead at 48 months. Those whose maximal heart rate was less than 120 beats/min had a 69% mortality at the end of 48 months of follow-up-. Therefore, the treadmill test, in addition to its diagnostic value, may be even important as an indicator of long-term prognosis. Data such as these, combined with radionuclide studies of ventricular function and long-term ECG monitoring for arrhythmia, will probably allow noninvasive definition of subgroups of even greater prognostic homogeneity than possible in the past with invasive study. If one could define by noninvasive testing subclasses of patients with nearly normal probability of survival, indications for coronary arteriography and surgery would be sharply diminished for these patients, in contrast to those in the subsets with extremely high mortality rates, in whom a very aggressive attitude would be justified.
The appropriate use of these various tests in the comprehensive evaluation of a patient with suspected coronary heart disease is addressed elsewhere in this symposium; but it is appropriate to emphasize the necessity for a high degree of selectivity in an efficient and cost-effective application of the various tests for evaluating patients with suspected coronary heart disease. Not all patients require all tests. Many patients require only a careful history and physical examination, with adequate explanation of the conclusions drawn. In other patients, a stress electrocardiographic test may be indicated; and this test frequently provides enough information to make diagnostic and therapeutic decisions. If the diagnosis remains in doubt, the next step might be radionuclide studies of coronary perfusion with thallium or radionuclide ventriculography at rest and with exercise. In patients with a very strong need for accurate diagnosis, the next step after stress electrocardiography is coronary arteriography. Such invasive study is also indicated in patients who have severely abnormal responses to stress testing, especially if these occur at low levels of exercise. In some patients, coronary arteriography should be performed after the history and physical ex-amination, resting ECG, chest x-rays and appropriate enzyme studies, especially patients with severe unstable angina or after nontransmural myocardial infarction. In general, coronary arteriography is indicated when there is substantial doubt of the diagnosis in patients with a valid "need to know" after noninvasive study and in those in whom there is significant evidence from noninvasive studies of severe coronary disease that justifies consideration for coronary bypass surgery.
Education
The second major facet of comprehensive medical management of the patient with coronary heart disease relates to education of the patient, and his family, physician, and the community (table 7) . Education of the patient and the family includes providing understandable information about the relevant anatomic and physiologic principles of coronary heart disease, its natural history and the present status of surgical intervention. Such understanding is crucial if the patient and family are to participate effectively in the decisions that affect the patient's life and chances of survival. In addition, to ensure effective compliance with the medical regimen, the patient and family must understand the reasons for the alterations in lifestyle and behavior that are advised.
Educating the community about atherosclerotic heart and vascular diseases and their pathogenesis and emergency management is vital in the long-term care of patients with these diseases. The community must be adequately prepared to cope with acute heart attack, with respect to both prehospital and hospital care.
Treatment
The third major aspect of the management of chronic coronary heart disease is the actual treatment of the patient after the diagnosis has been established. The fundamental goals of treatment are to prevent premature death and to enhance the quality of life (table 8) . The specific goals are to arrest or partially reverse the underlying process of atherosclerosis and to control the manifestations of coronary heart disease, including angina pectoris, potentially lethal arrhythmias, myocardial infarction and congestive heart failure.
Modification of Lifestyle -Control of "Risk Factors"
An essential element of overall management is the modification of lifestyle to relieve the patient of excessive physical and emotional stress and to control the major risk factors for coronary atherosclerosis. This pragmatic approach is widely practiced and is believed to be entirely justifiable in patients with coronary heart disease, despite the continuing lack of scientific certainty regarding the efficacy of some or all of these interventions. 24 26 In these patients, the course of wisdom clearly seems to lie in lifestyle changes rather than in continuing old and apparently destructive habits. For most patients, such modifications enhance rather than impair the quality of life. Many patients and their families find significant emotional relief in following a well-defined regimen that they perceive to be of probable value in long-term recovery.
There is strong evidence that some interventions may in fact decrease the probability of death in these patients. The evidence for this belief may be strongest in the case of cessation of cigarette smoking and in the treatment of hypertension. Epidemiologic evidence in- dicates that the significantly greater probability of heart attack in smokers compared with nonsmokers rapidly declines after smoking is discontinued, and approaches levels of persons who have never smoked. 26 There is evidence that these observations also apply to patients with established heart disease and that cessation of smoking may be a potent nonpharmaceutical therapeutic intervention that justifies strong efforts to persuade persons at risk to discontinue the habit (table   9 ). 27 The evidence that effective control of hypertension may prolong life, even in persons who have moderate hypertension, continues to mount with the recent reports of the Hypertension Detection and Follow-Up Program.28 This group recorded an overall reduction of more than 20% in mortality due to coronary and cardiovascular disease, with a reduction of all death by 17%. These figures refer to the mortality experience in a prospective randomized trail in patients with mild hypertension and no evidence of target organ disease at entry into the trial. The comparison was between the "stepped-care" group that received intensive treatment in special clinics and the group that receive "referred care" by their own physicians. Such interventions are made even more logical by the wellestablished role of blood pressure as a major determi- nant of myocardial oxygen consumption. Thus, controlling hypertension in such patients is generally recognized as being of great importance.
The control of physical inactivity (encouraging sedentary people to exercise) is a very popular intervention. Although there is no conclusive evidence that patients with coronary disease live longer if they exercise, properly selected patients can achieve a training effect (slowing of rest and exercise heart rates and increases in maximal oxygen uptake and maximal cardiac output).29831 I continue to be impressed with the major reassurance and reestablishment of selfconfidence that is achieved when the patient learns that, with proper pacing of his activities and in many cases with appropriate medications, including prophylactic nitrate administration (isosorbide dinitrate, chewed or sublingual, 5-10 mg, 2-3 minutes before stress), he can regularly complete a prescribed exercise regimen without symptoms and at levels that are often taxing to his friends without heart disease. In many instances, patients with severe multivessel coronary disease and significantly impaired ventricular function walk a mile or more once or twice daily and do so for years with the daily reassurance of the essential adequacy of their hearts and coronary circulation. Sometimes, the inability of a patient to perform an exercise of which he was previously capable alerts him and his physician to some change in his overall condition that requires evaluation and possible treatment. Thus, exercise provides a regular check of continued well-being. The patient must be carefully instructed to note such variations, to respond appropriately to them, and to report them to his physician without delay.
The control of hyperlipidemia is a complex and controversial subject.2' 32 9 Major therapeutic efforts are made in the younger patients, especially in those under 65 years of age, with significantly elevated serum lipid concentrations. In these patients, if vigorous dietary intervention does not result in optimal concentrations of serum lipids, then equally vigorous pharmacologic intervention is made. In general, the older the subject and the lower the lipid values, the less emphasis is given to the control of hyperlipidemia. However, most patients are instructed in and advised to follow the socalled prudent diet of the American Heart Association, which is relatively low in total and saturated fats, cholesterol and total calories.34 Many physicians will actively treat significant hypercholesterolemia even in older patients, but an effort is made not to cause unnecessary or unpleasant alterations in well-established dietary habits in very old patients. In most instances, dietary changes are easily adopted by the patient.
The control of obesity is perhaps our least successful venture. An initial weight loss is common, but so is a subsequent weight gain as the initial motivation wanes. Regular exercise is of great value in the controlling body weight, but fundamental research into factors determining maintenance of an optimal body fat content is required before an effective solution will be found to this extremely common and frustrating problem.
Control of Clinical Manifestations
The second specific goal of treatment is to control the clinical manifestations of chronic coronary heart disease, including angina, lethal arrhythmias, infarctions and congestive heart failure. Highest priority is given to maintaining optimal coronary blood flow by altering behavior and by pharmacologic intervention. In both cases, the primary goals of therapy are to reduce the oxygen requirement of the heart per beat by decreasing myocardial wall stress and tension through reductions in left ventricular volume, blood pressure and cardiac contractility; to control the heart rate to diminish the myocardial oxygen cost per minute;36' 36 and to directly improve coronary blood flow to the ischemic regions of the heart by agents that affect the coronary circulation.
The behavioral modifications are of great importance and include dietary alterations, such as sodium restriction to reduce blood pressure and ventricular volume, as well as the lipid restrictions already noted. The caloric intake is controlled to curb obesity and to minimize postprandial fluctuations in cardiovascular activity that may result in postprandial angina. At least partial control of emotional stress can be achieved in most patients by careful and caring interaction between the physician, the spouse and the patient. This entails examining both work and leisure schedules, habits and stress points, and proper education of the patient and his family as to the facts of his illness, including its natural history and treatment.
As the knowledge of the patient increases under the guidance of a wise and sympathetic physician, there is a strong tendency for the original fear of coronary disease to diminish. Additional reinforcement comes when the patient learns how to cope with an episode of angina correctly and with confidence. Even more reassurance comes as the ability to prevent episodes improves, ideally to the point of having few, if any, anginal episodes during the course of an active life.
Specific Pharmacologic Interventions
The Nitrates
The nitrates have been a mainstay of pharmocologic treatment of angina pectoris since the value of amyl nitrate in the treatment of angina was described in 1867 by Brunton97 and of nitroglycerin in 1879 by William Murrell."8 The basic pharmocologic effect of the nitrates is the widespread and nonspecific relaxation of smooth muscle, though this effect is most important in the case of vascular smooth muscle.39 The most striking cardiovascular responses are in the peripheral circulation, where marked dilatation of the capacitance vessels results in a gravity-determined diminution in venous return to the heart. This causes an immediate decrease in left ventricular volume.40 42 There is also relaxation of muscle in the large conductance arteries and a smaller but still significant relaxation of the arterioles. These changes produce a modest decrease in systemic vascular resistance. This, coupled with a marked decrease in venous return, results usually in some decrease in arterial pressure, more marked when the subject is standing. The decreases in II-8 CIRCULATION MEDICAL MANAGEMENT OF ANGINA/Reeves ventricular volume and systolic pressure combine through the LaPlace effect to decrease wall tension, a major determinant of myocardial oxygen requirement per beat. There is generally some reflex increase in myocardial contractility and heart rate, but the net effect is a marked decrease in myocardial oxygen requirement per minute, which reduces proportionately the demand for coronary blood flow. 43 The other major action of nitrates is on the coronary circulation, where the dominant effect is to dilate the large conductance vessels and any collateral vessels that may be present.44 4' Nitroglycerin improves regional coronary blood flow to ischemic areas in animals and in man.46 Although total coronary flow does not increase, both the systemic hemodynamic effects, resulting in decreased left ventricular wall stress, and the coronary effect probably account for improved regional blood flow and the relief of angina.
The Clinical Use of Nitroglycerin
Although nitroglycerin has long been used to treat angina, it is still not always used with precision. Patients often do not take nitroglycerin promptly because they believe that it may be an addicting or habituating analgesic. Another common error is to prescribe a dosage that is either too large, resulting in headache and hypotension, or too small, resulting in undesirable prolongation of angina. The proper dose can best be judged if the physician observes the patient's response to nitroglycerin at rest and during an episode of angina.
The Long-acting Nitrates
There is no reasonable doubt that long-acting nitrates have major and prolonged hemodynamic effects, even when taken by mouth. Earlier doubts as to their efficacy and the bioavailability of active forms of these nitrates after oral administration related to the fact that effective forms of the nitrates were not found in the blood of experimental animals after their ingestion. This finding suggested very rapid and complete biotransformation by the hepatic nitrate reductase systems and led to a strong skepticism on the part of many physicians and investigators as to the usefulness of these drugs.47 Further support for this negative view came from studies in humans when small doses of isosorbide dinitrate were given orally with negative results in controlled trials of exercise performance. More recently, investigators have studied larger doses of the longer-lasting nitrates, including oral and sublingual isosorbide dinitrate, nitroglycerin ointment and oral pentaerythritol tetranitrate.'8 5' These studies have shown major and prolonged hemodynamic changes, including diminution in left ventricular filling pressure and systolic and diastolic blood pressure. Thadani and colleagues65 reported dose-response studies of isosorbide dinitrate and published the time course of plasma concentrations of isosorbide dinitrate after single oral doses of 15, 30 and 60 mg. A sustained dose-related elevation of plasma concentrations for more than 8 hours occurred and marked hours, as did the improvement of treadmill exercise tolerance as gauged by both the time to onset of angina and of the prevention of ECG changes. This effect could have been caused by the decreased ventricular volume rather than by an increased regional coronary blood flow. Franciosa and Cohn"' reported that the hemodynamic effects are sustained and that singledose responsiveness was maintained over several months of continuous administration. Moreover, the nitrates provide effective relief of coronary arterial spasm in both induced and spontaneous forms, though apparently they are not as effective as calcium-blocking drugs. Overall, when long-acting nitrates are used in adequate doses (for example, isosorbide dinitrate doses of up to 240 mg/day) and are carefully titrated in each patient, they are of great value in the symptomatic management of the patient with severe angina. Another important application of long-acting nitrates is in the treatment of congestive heart failure, as both the preload and afterload can be reduced to the sustained benefit of the patient.67
Beta-adrenergic Blockers
Clinical experience in the United States with the fadrenergic blockers until very recently has been limited to propranolol. Metoprolol and atenolol, more cardioselective agents, are now available for clinical use, as are nadolol and timolol, which are longeracting, nonselective ,B blockers. Unlike the controversy over the value of the long-acting nitrates, there has been remarkable agreement as to the benefit of chronic administration of ,B blockers. Data from prospective randomized trials have shown reduced mortality among survivors of acute myocardial infarction. 68' 69 Although no such data demonstrate a favorable effect of the blockers on survival in patients with angina pectoris not related to acute infarction, there is little doubt as to the symptomatic relief obtained by these agents in persons with both stable and unstable angina. This improvement is brought about by reduction in myocardial oxygen requirements at rest and during exercise. This benefit results from major reductions in heart rate and by generally less marked but important reductions in blood pressure. A further diminution in oxygen requirement is produced by a decrease in myocardial contractility, as reflected by a decrease in the rate of pressure development in the ventricle. Propranolol also has effective antiarrhythmic properties and prevents both supraventricular and ventricular tachycardia.66 Undesirable effects include the druginduced increase in end-diastolic volume that accompanies the slowing of the heart rate and the decrease in contractility. Congestive failure may be precipitated in patients with impaired left ventricular function, although this occurs in surprisingly few patients. By relieving myocardial ischemia, propranolol paradoxically improves ventricular function in experimental animals and in man with acute left ventricular ischemia and failure. Crawford et al." demonstrated that digoxin and propranolol in combination tend to prevent the increase in heart size seen with prohemodynamic changes persisted for approximately 8 lI-9 pranolol alone and improve exercise capacity in VOL 65, SUPPL II, JUNE 1982 patients with impaired left ventricular function, compared with propranolol treatment alone.
The effective dosage of propranolol varies widely from patient to patient; individual titration against both rest and exercise heart rates while monitoring blood pressure and evidences of congestive failure is required. Jackson and colleagues"" reported that adjustment of dosage of A3 blockers to produce a maximal heart rate of 100 beats/min during exhausting exercise is sometimes necessary to control otherwise refractory angina. At times, it may be both necessary and effective in patients with relatively resistant angina to reduce resting heart rate to around 40 beats/min with these agents, usually in combination with high-dose nitrate therapy and digitalis in patients with compromised ventricular function. In patients with compromised ventricular function, excessive bradycardia may exacerbate angina or congestive failure. At times, it is helpful to implant a programmable cardiac pacemaker to allow adequate doses of a blocker to be used without excessive resting bradycardia.67
Combined Nitrates and Blockers
The combination of long-acting nitrates and ,B blockers is a commonly prescribed and very effective way to treat angina pectoris. Russek"' " reported that this combination allows the nitrates to be taken in high doses without reflex tachycardia or increased contractility. The decrease in venous return resulting from the nitrates offsets the tendency of propranolol to cause increased left ventricular diastolic volume, and the decrease in systemic vascular resistance lowers the blood pressure still further. The result is a decrease in ventricular wall stress. Indirectly, the nitrates tend to prevent the decrease in stroke volume resulting from the ,B blockers if given alone. Unfortunately, no data allow a confident assessment of the effect of such combinations on survival of patients with coronary heart disease and angina.
Calcium-blocking Agents
The calcium-blocking drugs, including verapamil, nifedipine, perhexiline maleate and diltiazem, constitute an important new family of pharmacologic agents for treating ischemic heart disease. 70 Although not yet released for prescription use in this country,* these agents have been intensively investigated in recent years, and have been known for almost 20 years. Although they all inhibit calcium transport via the "slow channel" of the cellular membrane and reduce the contractile state of cardiac and vascular smooth muscle, the various calcium blockers have significantly different actions with respect to myocardial contractility, systemic arteriolar resistance, coronary vasodilatation, venomotor tone and antiarrhythmic properties. These agents will probably assume an important role in the treatment of variant angina and angina due to coronary atherosclerosis.
The recent studies of Maseri and associates have provided important new insight and renewed interest in coronary arterial spasm. These investigators have reported that in hemodynamic and myocardial perfusion studies, coronary spasm may be important not only in persons with variant angina, but also in those with unstable angina.71 In addition, coronary spasm may be at least partially responsible for acute infarction in persons with severe coronary stenosis and for a significant fraction of sudden cardiac death. The experience in treating variant angina with slow-channel inhibitors has been extremely encouraging.72 78 In addition to preventing and relieving spasm, these drugs dilate the epicardial conductance vessels, possibly including the stenosed sections of the arteries. They also dilate systemic arterioles, thereby decreasing blood pressure and afterload with relatively little change in venous return and preload. They have variable effects on heart rate and some variable negative inotropic influences. The latter tend to be obscured in the intact animal or human by reflex changes and by the facilitation of ejection that accompanies the diminution in afterload. These agents have been reported to greatly diminish the frequency of angina episodes in persons with vasospastic angina. They have also been reported to be of value in patients with fixed obstruction angina refractory to A blockers and high-dose nitrate therapy.
Methods for clinical use of the calcium-channel blockers are still evolving. When given to patients with "fixed" coronary atherosclerosis and angina pectoris, nifedipine is usually started in doses of 10 mg, two or three times daily rapidly increased as tolerated and required to a usual maximal dosage of 120-160 mg/day. If necessary, nifedipine can be added to the , blockers and long-acting nitrates if these agents are already being used to treat angina, but care must be taken when nifedipine is added to the d blockers in patients with impaired left ventricular function. The net effect of nifedipine on ventricular performance is not ordinarily detrimental, because the negative inotropic effect of the calcium-channel blockade with nifedipine is balanced by its reduction of systemic vascular resistance and blood pressure. In patients with severe symptoms, all three agents may be used to advantage, as each has unique properties that collectively may lead to a balance between myocardial oxygen demand and delivery.
Thus, the nitrates provide for diminution in preload; the blockers for reduction in heart rate, contractility and blood pressure; and nifedipine for improvement in coronary blood flow. Nifedipine also diminishes arteriolar resistance, systolic blood pressure and afterload.
It is not completely clear in which sequence these drugs should be introduced. In variant angina, the calcium-channel blockers appear to be the agent of first choice. If the patient's abnormalities are not properly controlled by full doses (160 mg/day), nitrates should be added. In chronic stable angina, blockers would usually be the first choice because of their documented effect upon survival of patients with established coronary disease. The calcium-channel blockers might be prescribed next, and the long-acting nitrates added last, if still required. Sequential treadmill testing is frequently helpful in assessing the need for treatment and the response of the patient to pharmacologic interventions. Intelligent use of these agents will probably significantly decrease the need for coronary bypass surgery to relieve intractable angina.
These slow-channel inhibitors may'be'of such importance as to require careful reevaluation of the survival characteristics of subclasses of persons with chronic ischemic heart disease after the agents are introduced-into clinical practice. Very careful thought must be given as to the most appropriate and efficient methods for evaluating the impact of these drugs on treatment of patients with coronary heart disease and on their survival and-quality of life. Consideration should be given to organizing comparative studies of quality of life and survival in patients treated with these agents alone and in combination with long-acting nitrates and ,B blockers, in addition to' the necessary lifestyle interventions. Innovative approaches to clinical trials are needed to provide meaningful clinical answers without greatly' increased expense. Both public and private sectors should cooperate in the funding of such trials and in their critical design. Trials could probably be based on' patients already meticulously studied and indexed into the National Heart, Lung, and Blood Institute's Coronary Artery Surgery Study (CASS) registry.74
Newer Antiarrhythmics
Until recently, few antiarrhythmic agents have been available to the clinician. This is still true in the U.S., where quinidine, procaineamide, the , blockers, dilantin and disopryamide are the only 'oral antiarrhythmic drugs released for prescription use. The side effects and limited value of these agents in many arrhythmias have left many patients with ischemic heart disease without effective control of arrhythmias. Now, several new drugs, including mexiletine, tocainide, aprindine, lorcainide, flecanide, encainide, ethmogen and amiodarone, in addition to the calcium blockers, are receiving intensive controlled clinical evaluation. If these agents live up to their promise, we should see a new era of-arrhythmia control.76' 70
Antiplatelet Aggregants
Many physicians now prescribe the antiplatelet drugs aspirin, dipryridamole and sulfinpyrazone for patients with coronary heart disease, including those with angina pectoris. Interest in these agents has increased steadily, and their antithrombotic effects have been evaluated in patients with transient ischemic attacks and after myocardial infarction, as well as in patients with prosthetic heart valves and those at increased risk of pulmonary embolization. In patients with coronary disease, all recognized major trials reported to date have been concerned with the effect of these agents upon survival after acute myocardial infarction. None of the seven major trials recently reviewed,59 involving over 13,000 patients, has shown a definite benefit of platelet-active drugs in postinfarction patients. However, positive trends supporting a possible reduction in mortality were reported in all except the largest, the Aspirin Myocardial Infarction Study. In this study of 4524 subjects, the aspirintreated group had a slightly higher mortality rate than the placebo group. Retrospective analysis of both the Persantine (dipyridamole) and Anturane (sulfinpyrazone) reinfarction trial's suggests that any apparent beneficial effect was limited to the first 6 months'after acute myocardial infarction; this possibility requires confirmation. Despite the great appeal of the antiplatelet drugs on theoretical grounds, no firm data are available upon which to base advice for patients with un'complicated angina pectoris. Many physicians prescribe aspirin for patients who survive acute myocardial infarction, starting during hospitalization, recognizing the absence of firm data upon which such advice is based. 'The optimal dosage is also controversial. However, most of the trials reporting a beneficial result have used a daily dose of at least 900 mg.68 consider how operative treatment can affect this process in four ways: relief of angina pectoris, prolongation of life, the freedom of improved function, and the consolation of maximum redress.
Relief of Angina Pectoris
Angina pectoris is an oppressive symptom for many people, especially for patients who have experienced a myocardial infarction or have an identified arterial obstruction that deprives the heart of adequate blood flow. Even if convinced that angina pectoris is not a determinant of longevity, concerned physicians and thoughtful patients seek its remedy both for relief of pain and for freedom from its symbolism of unfitness, disability, restricted performance and death. John Hunter, who is believed to have died of a myocardial infarction immediately preceded by angina induced by an argument during a board meeting at St. George's, drew a relationship between his chest pain and his mortality: "My life is in the hands of any rascal who chooses to annoy and tease me."2
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